Ignore the Vaccine Noise, Johnson & Johnson Is in Rude Health, Says Top Analyst

It has been an action-packed week so far for pharma giant Johnson & Johnson (JNJ).On Tuesday, the company reported Q3 earnings with results handily beating the estimates. JNJ posted revenue of $21.08 billion, a 1.7% year-over-year increase and higher than the $20.21 billion consensus estimate. Non-GAAP EPS of $2.20 beat the Street’s forecast by $0.22.Looking ahead, JNJ raised its 2020 guidance and now expects revenue to come in between $81.2 billion to $82.0 billion, up from the previous call for between $79.9 billion and 81.4 billion. Non-GAAP EPS was also raised from $7.85 at the mid-point to $8.00 at the …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.